NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $14.00 price target on the stock.

Several other analysts also recently issued reports on NRSN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Finally, Roth Mkm initiated coverage on shares of NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Trading Down 5.1%

Shares of NRSN opened at $0.72 on Wednesday. The firm’s 50-day moving average is $0.86 and its two-hundred day moving average is $0.98. NeuroSense Therapeutics has a twelve month low of $0.63 and a twelve month high of $2.60. The firm has a market capitalization of $23.48 million, a P/E ratio of -1.34 and a beta of 1.70.

Hedge Funds Weigh In On NeuroSense Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of NRSN. Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics during the fourth quarter valued at approximately $77,000. Squarepoint Ops LLC lifted its stake in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after buying an additional 45,450 shares during the period. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics during the second quarter valued at approximately $54,000. Finally, Two Sigma Investments LP purchased a new position in NeuroSense Therapeutics during the third quarter worth approximately $26,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.